Biohit Oyj - Company Announcement

Stock exchange release

Helsinki, Finland, 2011-12-28 12:02 CET (GLOBE NEWSWIRE) -- 

Communications procedure of Biohit Oyj on the publication of a press release on
business sales 


Biohit Oyj
Stock exchange release
28 December 2011 at 13:00 P.M.


NASDAQ OMX Helsinki issued today a public reprimand to Biohit Oyj concerning
the publication of its company announcement from 26 October 2011on the sale of
its Liquid Handling business. The service provider in charge of publishing
Biohit Oyj's stock exchange releases published the release on the Biohit news
archive web pages before its release on the Biohit news page, which led to an
unfortunate leak of information 49 minutes before the publication of the actual
release. 

This was a technical error on the part of the service provider and it will not
happen again. In spite of this, Biohit Oyj will work to improve its information
and follow-up processes to avoid the possibility of similar mistakes. 




For further details, contact:

Osmo Suovaniemi
MD, PhD, Professor
Chairman of the Board of Directors
Tel. +358 40 745 5605
osmo.suovaniemi@biohit.fi


Distribution:

NASDAQ
OMX Helsinki Oyj
Central Storage Facility (www.oam.fi)
Press
www.biohit.fi



About Biohit

Biohit Oyj is a globally operating Finnish biotechnology company established in
1988. Biohit's mission crystallises in its motto “Innovating for Health”. The
company assumes social responsibility by producing innovations, new
technologies and analysis systems for use in medicine, research institutions
and industry. These products help to promote research and diagnostics, while
improving quality of life by preventing disease, human suffering and financial
loss. Biohit also seeks to innovate and develop the marketing and availability
of its products and services, in order to ensure its profitable growth and
ability to pay dividends. 
Biohit works with scientific communities to produce new technologies, products
and services based on research results and innovations. These can be used to
develop safe and cost-effective diagnostic tests for the early detection and
prevention of diseases of the gastrointestinal tract. (www.biohit.fi /
International / State of the art GastroPanel and Acetium innovations for the
unmet need) 

Biohit's products include analysis systems for the prevention and early
diagnosis of gastrointestinal diseases, such as the blood-sample based
GastroPanel examinations for the diagnosis of stomach illnesses and associated
risks, quick tests for the diagnosis of lactose intolerance and H. pylori
infection in connection with gastroscopy, and the ColonView examination for the
early detection of intestinal bleeding that indicates a risk of colorectal
cancer. Acetium reduces the amount of carcinogenic acetaldehyde in an anacidic
stomach. (www.acetium.com/test - reveals acetaldehyde exposure) 

Biohit employs around 35 people. The company is headquartered in Helsinki,
Finland and has a subsidiary in the UK. Since 1999, Biohit's Series B share
(BIOBV) has been quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare
group and is traded under the code BIOBV (www.biohit.fi). 



Read more at www.biohit.fi